



Nanoparticles could Improve the Efficiency of CAR-T Immunotherapy for Cancer

Ida Franiak-Pietryga*

Department of Clinical and Laboratory Genetics, Medical University of Lodz, Poland

Editorial

CAR-T immunotherapies are the cutting-edge topics of research and investment recently. The emerging leukemia treatments have had amazing success in the past few years, even curing patients with progressive and terminal phase of the disease. Chimeric Antigen Receptors (CARs) are a type of antigen-targeted receptor composed of intracellular T-cell signaling domains fused to extracellular tumor-binding moieties, most commonly single-chain variable fragments (scFvs) from monoclonal antibodies. CARs directly recognize antigens on the cell surface, independent of MHC-mediated presentation, approving the use of a single receptor specific for any given antigen in all patients. Initial CARs fused antigen-recognition domains to the CD3 activation chain of the T-Cell Receptor (TCR) complex. CAR-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. To date, it has been most widely studied and most successful in that group of patients, targeting the differentiation antigen CD19 expressed by normal B-lymphocytes at the National Cancer Institute (NCI), Memorial Sloan-Kettering Cancer Center (MSKCC), the University of Pennsylvania (UPenn), and University of California San Diego [1]. The first report of antitumor activity occurred at the NCI in a patient with follicular lymphoma using second-generation CAR-T cells derived from the murine FMC63 antibody specific for human CD19 and a CD28 costimulatory signaling domain [2].

However, the CAR-T cell therapy targeting other cancers, it has been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. While the first generation CARs were largely limited by poor antitumor efficacy *in vivo*, the second and third generation CARs dramatically improved antitumor efficacy [3]. In some cases they led to complete remissions in patients with advanced cancer [2,4-7]. The increased potency of second and third generation CARs is obvious; however it might also increase the risk of severe toxicities.

OPEN ACCESS

*Correspondence:

Ida Franiak-Pietryga, Department of Clinical and Laboratory Genetics, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, Poland, E-mail: ida.fp@interia.pl

Received Date: 11 Jul 2018

Accepted Date: 30 Aug 2018

Published Date: 06 Sep 2018

Citation:

Franiak-Pietryga I. Nanoparticles could Improve the Efficiency of CAR-T Immunotherapy for Cancer. *Am J Leuk Res.* 2018; 2(2): 1013.

Copyright © 2018 Ida Franiak-Pietryga. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The first report of clinical use CAR-T cell treatment as well as toxicities following occurred in a study of first generation CAR-T cells targeting carboxy-anhydrase-IX (CAIX) in three patients with metastatic clear cell Renal Carcinoma (RCC). Unfortunately, the treatment causing CAIX-targeted destruction of these cells produced the hepatotoxicity [8]. The next reported a third-generation CAR-T cell treatment targeting epidermal growth factor receptor 2 (ERBB2, HER2) occurred in a patient with colorectal cancer metastatic to the lung and liver [9]. The patient developed severe side effect such as respiratory distress within 15 minutes of receiving a single dose of 10^{10} CAR-T cells. Second-generation CARs have recently been explored targeting mesothelin, an antigen overexpressed by Malignant Pleural Mesotheliomas (MPM), pancreatic, ovarian, and a subset of lung cancers [10]. To decrease the severe side effects of CAR-T therapy the clinical trial (NCT02159716) has been ongoing using lentivirus -engineered CARTmeso cells.

Bringing CAR-T immunotherapies into solid tumors is the next cutting edge of the technology, and a new approach from the Fred Hutchinson Cancer Research Center may help it along the way. The research team led by Dr. Matthias Stephan demonstrated how they used nanotechnology to solve the tumor-targeting problem and decrease the price of therapy. They demonstrated that once they adapted with lymphocyte-targeting ligands, polymeric nanocarriers can selectively deliver leukemia-specific CAR genes into host T cells *in situ* [11]. To achieve effective nucleic acid delivery into T cells, genes carriers must be taken up by T cells, and import their DNA cargo into the cell nucleus.

Recently, the researchers used tiny, biodegradable nanoparticles to deliver two drugs directly and simultaneously into solid tumors. The drugs worked together to shut down the tumors' defense

mechanisms and rally the immune system. That opens the door for CAR-T treatments, which are made up of genetically modified immune cells, to come in and attack the cancer cells. The finding is important because it could help target CAR-T treatments directly at tumors instead of sending them coursing throughout a patient's body, which leads to potentially dangerous side effects.

We are the witnesses of the new era of medications. CAR-T therapy already proved its superiority to the other therapies. CAR-T cells showed already clear therapeutic benefits in patients with CD19⁺ malignancies. The ability to engineer T cells with a desired specificity through the use of CARs has induced a profound effort to extend this approach to other antigen targets and solid tumors. Expanded clinical use of CAR-T cells will provide further insights into proper dosing regimens and patient monitoring strategies that will provide safe administration, while maximizing clinical benefit.

References

1. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. *Cancer J*. 2014;20(2):112-8.
2. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood*. 2012;119(12):2709-20.
3. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhali M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proc Natl Acad Sci USA*. 2009;106(9):3360-5.
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med*. 2013;368(16):1509-18.
5. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med*. 2011;3(95):95ra73.
6. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. *Blood*. 2013;122(25):4129-39.
7. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol*. 2015;33(6):540-9.
8. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. *J Clin Oncol*. 2006;24(13):e20-2.
9. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther*. 2010;18(4):843-51.
10. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunol Res*. 2014;2(2):112-20.
11. Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reimen D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. *Nature Nanotechnology*. 2017;12:813-20.